by Shernan Holtan, MD
This spotlight features Shernan Holtan, MD, chief of blood and marrow transplantation at Roswell Park. A leader in regenerative therapies and GVHD research, she shares the early experiences that...
by Spandidos Publications
Programmed cell death 1 (PD-1) ligands may be part of the challenge in applying chimeric antigen receptor (CAR) T-cell therapy to solid tumors but, researchers suspect, they also could be part of...
by Clinical Cancer Research
Study results indicate that cell therapy using B7 homolog 3 (B7-H3/CD276) may be a promising pathway in the pursuit of targeted therapies to treat ependymomas (EPNs).
by The New England Journal of Medicine
Protection against graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (SCT) typically includes a calcineurin inhibitor plus an antimetabolic, but evidence supports adding...
by Nature
Despite a lack of long-time evidence demonstrating the value of allogeneic hematopoietic cell transplantation (allo-HCT) in older adults with Philadelphia-positive acute lymphoblastic leukemia,...
by Sita Bhella, MD, MEd, FRCPC
Immune effector cell-associated neurotoxicity syndrome is a complication of chimeric antigen receptor T-cell therapy. The condition is characterized by neurologic symptoms, such as tremors,...